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Background: Enterohepatic bacterial infections have the potential to affect multiple physiological processes of the
body. Fibroblast growth factor 15/19 (FGF15 in mice, FGF19 in humans) is a hormone that functions as a central
regulator of glucose, lipid and bile acid metabolism. FGF15/19 is produced in the intestine and exert its actions on
the liver by signaling through the FGFR4-βKlotho receptor complex. Here, we examined the in vivo effects of
enterohepatic bacterial infection over the FGF15 endocrine axis.
Results: Infection triggered significant reductions in the intestinal expression of Fgf15 and its hepatic receptor
components (Fgfr4 and Klb (βKlotho)). Infection also resulted in alterations of the expression pattern of genes
involved in hepatobiliary function, marked reduction in gallbladder bile volumes and accumulation of hepatic
cholesterol and triglycerides. The decrease in ileal Fgf15 expression was associated with liver bacterial colonization
and hepatobiliary pathophysiology rather than with direct intestinal bacterial pathogenesis.
Conclusions: Bacterial pathogens of the enterohepatic system can disturb the homeostasis of the FGF15/19-FGFR4
endocrine axis. These results open up a possible link between FGF15/19-FGFR4 disruptions and the metabolic and
nutritional disorders observed in infectious diseases.
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Alteration of the host’s metabolism is common in infec-
tious diseases; it can lead to patient malnutrition and the
need for nutritional support [1,2]. Infection-driven meta-
bolic changes are characterized by an accelerated flux of
glucose, lipids, proteins and amino acids that may result
in net protein loss and diabetic-like hyperglycemia [1,2].
Significant metabolic disorders have been observed in
natural and experimental infections with the bacterium
Salmonella enterica, including changes of the lipid and
protein profiles and widespread hormonal imbalances
[1,3,4]. In humans, Salmonella enterica serovar Typhi
causes typhoid fever, a disease characterized by multi-
organ bacterial colonization with common immunopa-
thological manifestations in the gastrointestinal tract and
the hepatobiliary system [5].* Correspondence: alfredo.menendez@usherbrooke.ca
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reproduction in any medium, provided the orThe molecular and physiological bases of the metabolic
disorders observed during infection are not fully under-
stood. In this work, we examined the disruption of the
enterohepatic fibroblast growth factor 15/19 (FGF15/19)-
fibroblast growth factor receptor 4 (FGFR4) endocrine
axis during bacterial infections of the enterohepatic sys-
tem. FGF15/19 (FGF15 in mice, FGF19 in humans) is an
endocrine factor secreted by intestinal enterocytes [6].
FGF15/19 has a crucial role in the control of whole body
glucose and lipid metabolism and energy expenditure
[7,8]. It is also a key regulator of de novo synthesis of bile
acids via the repression of cholesterol 7 alpha hydroxylase
(CYP7A1) expression in hepatocytes [9]. In addition,
FGF15 represses the apical Na+-dependent bile acid trans-
porter (ASBT) expression in hepatic cholangiocytes [10]
and facilitates gallbladder filling by promoting gallbladder
muscle distension [11]. Through these functions, FGF15/19
closes an important negative feedback loop in the regula-
tion of bile acid homeostasis. Signaling to hepatic target
cells occurs through the interaction of FGF15/19 with the
tyrosine kinase receptor fibroblast growth factor receptorl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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genetically deficient for Fgf15, Fgfr4 or Klb (βKlotho) have
similar biliary phenotypes with higher levels of CYP7A1
and increased synthesis of bile acids [6,12-14]. Reduced
FGF19 levels have been observed in patients with inflam-
matory bowel disease [15] and chronic idiopathic bile acid
diarrhea [16]. On the other hand, patients with insulin
resistance and non-alcoholic fatty liver disease, as well as
extrahepatic cholestasis frequently display elevated plasma
levels of FGF19 [17,18].
Using a model of murine typhoid fever, we demonstrate
that Salmonella enterica infection triggers major alte-
rations in the hepatic biliary function gene expression pro-
gram, promotes accumulation of hepatic cholesterol and
triglycerides and leads to a significant reduction in physio-
logical gallbladder bile volumes. In addition, Salmonella
infection causes a substantial decrease in the expression of
intestinal Fgf15, accompanied by a dramatic loss of hepatic
FGFR4 and βKlotho. These disturbances appear to be
secondary to hepatic inflammation. Given the important
role of the FGF15/19-FGFR4 endocrine axis as a central
metabolic regulator, these alterations may be a major fac-
tor underlying the pathophysiology of bacterial infectious
diseases.
Methods
Bacterial strains and mouse infections
Salmonella enterica serovar Typhimurium strains SL1344
(Smr) and SB103 (invA) [19] and Listeria monocytogenes
10403 s (Smr) [20] were used in this study. Bacteria were
grown overnight at 37°C in LB supplemented with
100 μg/mL streptomycin. Inoculum was prepared in
sterile HEPES 100 mM, NaCl 0.9%, pH 8.0. Animal pro-
tocols were approved by the Animal Care Committees of
the University of British Columbia and the University of
Sherbrooke. Eight weeks-old female C57BL/6 mice (The
Jackson Laboratory, Bar Harbor, USA) were infected orally
with 5 × 107 Salmonella SL1344, intravenously with
5 × 102 Salmonella SB103 or with Listeria 10403 s (2 × 109
bacteria orally and 104 intravenously). The animals were
kept with food and water ad libitum through the duration
of the study and were always sacrificed during the light
period (10:00 AM± 60 minutes). The bile was collected by
gallbladder resection and draining by puncture. For bac-
terial counts, tissues were homogenized using a Mixer
Mill MM400 (Retsch GmbH) followed by plating of serial
dilutions in LB plates containing 100 μg/mL streptomycin.
All infection experiments were done in duplicate using a
total of 8–10 mice per group.
Expression analyses
Ileum and liver samples were collected for mRNA and
protein analysis. The ileal samples were taken appro-
ximately 2 cm away from the ileo-cecal junction; liversamples were taken from the central lobule. RNA was ex-
tracted using the RNeasy kit (Qiagen) and cDNA was pre-
pared using the Quantitech Reverse Transcription kit
(Qiagen). Quantitative PCR (qPCR) were done on an
Eppendorf RealPlex2 system using the DyNamo SYBR
Green qPCR Kit (Thermo Scientific). All reactions were
done in 10 μl final volume with 40 cycles of 30 seconds
denaturing at 95°C, 30 seconds annealing at 60°C and
30 seconds extension at 72°C (except the annealing
temperature for Ostβ: 62°C). The relative expressions were
calculated using the ddCt method and corrected for
primer efficiencies according to Pfaffl et. al. [21]. The
qPCR primers are listed in Table 1. Western blots were
performed using total liver tissue lysates and anti-
bodies against CYP7A1 (Abcam, ab65596, 1:1000),
FGFR4 (Abcam, ab119378, 1:500), βKlotho (R&D,
AF2619, 1:2000) and actin (SIGMA A4700, 1:1000).
Microscopy
For histological analysis, tissue sections were fixed in 10%
buffered formalin, embedded in paraffin and stained with
H&E. Alternatively, samples fixed in 3.5% paraformal-
dehyde and frozen-embedded in OCT were used for
immunofluorescent microscopy as previously described
[22]. Fluorescence was visualized using an Olympus IX81
microscope.
Cholesterol and triglyceride determinations
Cholesterol and triglycerides were assayed in liver
lysates. A total of 40-100 mg of liver was homogenized
with an ultra turrax (setting 5, 4 times for 15 sec) in
3 ml of chloroform:methanol (2:1), extracted twice with
water, and centrifuged for 15 minutes at 3000 g. For the
triglyceride assay 200 μl of the organic layer (lower
phase) was removed and evaporated under N2(g). 10 μl
of Thesit (Sigma-Aldrich, St Louis, MO) was added and
mixed under N2(g). Water (50 μl) was added and incu-
bated at 37°C for 1 hr with intermittent vortexing. Ali-
quots of 5 μl were assayed using the Serum Triglyceride
Determination kit (Sigma-Aldrich, St Louis, MO) modi-
fied for a 96-well plate, calibrated with a trioleate
(Sigma-Aldrich, St Louis, MO) standard curve. The
cholesterol assay was performed at the same time but
500 μl of the organic layer (lower phase) was removed
after the centrifugation step and evaporated under N2(g).
50 μl of isopropanol was then added to the dried down
lipids and mixed by vortexing. Aliquots of 2 μl were then
assayed using the Cholesterol E kit (Wako Chemicals
USA, Richmond, USA).
Statistical analyses
Data processing and statistical analyses were performed
using GraphPad Prism5. Student’s t test was applied
to all sets of data for statistical comparisons between
Table 1 The genes analyzed in this study and the sequences of the qPCR primer sets
Gene Official symbol Product Primers
Abcg5 Abcg5 ATP-binding cassette, sub-family G (WHITE), member 5 TGTCAACAGTATAGTGGCTCTG
CGTAAAACTCATTGACCACGAG
Abcg8 Abcg8 ATP-binding cassette, sub-family G (WHITE), member 8 CTTGTCCTCGCTATAGCAACC
TTTCCACAGAAAGTCATCAAAGC
Asbt Slc10a2 Apical sodium-dependent bile acid transporter ACCTTCCCACTCATCTATACTG
CAAATGATGGCCTGGAGTCC
Bsep Abcb11 Bile salt export pump CAACGCATTGCTATTGCTCGG
TAGACAAGCGATGAGCAATGAC
Cyp7a1 Cyp7a1 Cholesterol 7 alpha hydroxylase GGGAATGCCATTTACTTGGATC
TATAGGAACCATCCTCAAGGTG
Fabp6 Fabp6 Fatty acid binding protein 6 GAATTACGATGAGTTCATGAAGC
TTGCCAATGGTGAACTTGTTGC
Fgf15 Fgf15 Fibroblast growth factor 15 AGACGATTGCCATCAAGGACG
GTACTGGTTGTAGCCTAAACAG
FgfR4 Fgfr4 Fibroblast growth factor receptor 4 CTCGATCCGCTTTGGGAATTC
CAGGTCTGCCAAATCCTTGTC
FXR Nr1h4 Farnesoid X receptor (nuclear receptor subfamily 1, group H, member 4) GTTCGGCGGAGATTTTCAATAAG
AGTCATTTTGAGTTCTCCAACAC
βKlotho Klb Beta Klotho AACAGCTGTCTACACTGTGGG
ATGGAGTGCTGGCAGTTGATC
Mdr1a Abcb1a ATP-binding cassette, sub-family B member 1a CCGATAAAAGAGCCATGTTTGC
CTTCTGCCTGATCTTGTGTATC
Mdr1b Abcb1b ATP-binding cassette sub-family B member 1b GGACCCAACAGTACTCTGATC
ACTTCTGCCTAATCTTGTGTATC
Mdr2 Abcb4 Multidrug resistance protein 2 TTGTCAATGCTAAATCCAGGAAG
AGTTCAGTGGTGCCCTTGATG
Mrp2 Abcc2 ATP-binding cassette, sub-family C (CFTR/MRP) member 2 GGCTCATCTCAAATCCTTTGTG
TTTTGGATTTTCGAAGCACGGC
Mrp3 Abcc3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 GAACACGTTCGTGAGCAGCC
ATCCGTCTCCAAGTCAATGGC
Mrp4 Abcc4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 TACAAGATGGTTCAGCAACTGG
GTCCATTGGAGGTGTTCATAAC
Ntcp Slc10a1 Sodium-taurocholate co-transporting polypeptide CGTCATGACACCACACTTACTG
GATGGTAGAACAGAGTTGGACG
Osta Osta Organic solute transporter alpha TCTCCATCTTGGCTAACAGTG
GATAGTACATTCGTGTCAGCAC
Ostb Ostb Organic solute transporter beta CCACAGTGCAGAGAAAGCTGC
ACATGCTTGTCATGACCACCAG
Shp Nr0b2 Small heterodimer partner AGTCTTTCTGGAGCCTTGAGC
TTGCAGGTGTGCGATGTGGC
Romain et al. BMC Microbiology 2013, 13:238 Page 3 of 10
http://www.biomedcentral.com/1471-2180/13/238
Table 1 The genes analyzed in this study and the sequences of the qPCR primer sets (Continued)
SrbI Scarb1 Scavenger receptor class B type 1 GAACTGTTCTGTGAAGATGCAG
GCGTGTAGAACGTGCTCAGG
36B4 Rplp0 Ribosomal protein, large, P0 TCTGGAGGGTGTCCGCAAC
CTTGACCTTTTCAGTAAGTGG
The top sequence of each set corresponds to the forward primer and the bottom one to the reverse. All reactions were done in 10 μl final volume with 40 cycles
of 30 seconds denaturing at 95°C, 30 seconds annealing at 60°C and 30 seconds extension at 72°C (except annealing temperature for Ostβ, which was 62°C).
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errors of the mean.
Results
Enterohepatic infections downregulate the expression of
intestinal Fgf15
The terminal ileum is the main site of production of
FGF15, it is also a major port of entry for Salmonella and
therefore, an important site for its pathogenesis. To deter-
mine the effect of Salmonella infection on the homeo-
static synthesis of FGF15, we collected tissue samples
from infected animals and analyzed the abundance of
Fgf15 transcripts by qPCR. As shown in Figures 1A and
1B, the level of Fgf15 transcripts inversely correlated with
bacterial counts in the liver and the ileum, with a statis-
tically significant decrease observed at mid-high infectionFigure 1 Oral infection with Salmonella typhimurium SL1344 decrease
infected ilea and livers; animals were arbitrarily grouped into low, medium
respectively roughly corresponding to 72, 96 and 120 hours post-infection;
infected mice (data by qPCR). (C) H&E staining of ileum sections from repre
colonization of the infected animal = 2.2 × 106 cfu/mg); scale bars are 200 μ
and orally Salmonella-infected animals (liver colonization of the infected anlevels. While H&E-stained sections from the ileum of
infected animals did not show signs of pathological alte-
ration (Figure 1C), staining of liver sections demonstrated
a strong inflammatory response evidenced by large lesions
with widespread lymphocytic infiltration, extensive necro-
sis often accompanied by local hemorrhage, and zones of
parenchymal degeneration characterized by disappearance
of hepatocytes (Figure 1D).
FGF15 is synthesized by enterocytes [6], which can also
be invaded by Salmonella [23]. However, the decrease in
Fgf15 expression was not associated with damage to the
ileal enterocyte layer (Figure 1C). This suggests that loss
of ileal enterocytes is not the reason for reduced Fgf15
transcript levels. Oral infections with Listeria monocyto-
genes, an inefficient invader of the mouse intestinal epithe-
lium [24,25], showed no significant liver colonization ands the expression of Fgf15 in the ileum. (A) bacterial counts in
and high infection levels (100-103, 104-105 and >106 cfu/mg,
UI: uninfected). (B) relative levels of Fgf15 transcripts in the ilea of
sentative uninfected and orally Salmonella-infected animals (ileal
m. (D) H&E staining of liver sections from representative uninfected
imal = 1.7 × 105 cfu/mg); scale bars are 800 and 400 μm.
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lation of Fgf15 expression (Figure 2A). In contrast, intra-
venous infections with Listeria, which colonized the liver
rapidly and triggered deccreases in the transcript levels of
biliary function genes (Figure 2B), caused a significant re-
duction in ileal Fgf15 expression (Figure 2A). These results
point to hepatic pathophysiology, rather than intestinal
bacterial colonization, as the primary event driving down-
regulation of intestinal Fgf15 expression.
To establish the role of hepatic colonization and to
probe the involvement of bacterial enterocyte invasion
in repressing Fgf15 expression, we carried out intrave-
nous infections with the Salmonella invasion-deficient
strain SB103 following Menendez et al. [22]. In this type
of infection, Salmonella colonization of the hepatobiliary
system occurs immediately whereas colonization of the
gut is delayed by 72 to 96 hours [22]. Furthermore, the
bacteria that eventually reach the intestines are unable
to invade the enterocytes due to the invA mutation of
this strain. As shown in Figure 2C, intravenous infection
with Salmonella SB103 caused a reduction of Fgf15 tran-
scripts abundance. Notably, such a decrease was observedFigure 2 Liver colonization drives the downregulation of ileal Fgf15 e
infected orally or intravenously with Listeria monocytogenes. (B) transcript le
intravenously with Listeria monocytogenes, relative to the levels of uninfecte
transcripts in the ilea of mice infected intravenously with Salmonella typhim
qPCR, *p < 0.05.with a much lower intestinal bacterial burden than those
in oral infections with the wild-type strain (average 102 vs.
107 cfu/mg, respectively). These results demonstrate that
colonization of the hepatobiliary system by Salmonella
represses the expression of intestinal Fgf15 and show that
enterocyte invasion by intestinal bacteria does not play a
major role on this effect.
Transcription of Fgf15 in ileal enterocytes is trans-
activated by the nuclear receptor FXR (Farnesoid X
Receptor), upon its activation by bile acids [7]. Expression
of the FXR gene (Nr1h4) was not affected by Salmonella,
regardless of the intestinal bacterial burden (data not
shown). In contrast, the expression of other known intes-
tinal FXR target genes, Fabp6 (Fatty acid binding protein
6), Nr0b2 (Small heterodimer partner, Shp) [26] and Osta
(Organic solute transporter alpha) [27], was decreased by
Salmonella infection in a pattern similar to that of Fgf15
with maximal, significant drops in highly-infected animals
(Figure 3A). This suggests that activation of gene expres-
sion mediated by FXR is impaired during infection.
Colonization of the hepatobiliary system by Salmonella
induces local pathological damage and inflammation [22],xpression. (A) relative levels of Fgf15 transcripts in the ileum of mice
vels of genes involved in liver biliary metabolism in mice infected
d animals (defined as 1, dashed line). (C) relative levels of Fgf15
urium SB103 (invA), at 120 hours post-infection. Data by
Figure 3 Infection with Salmonella decreases the expression of FXR-target genes in the ileum. (A) Relative levels of Fabp6, Nr0b2 and Osta
transcripts in the ileum of mice orally infected with Salmonella typhimurium SL1344. Animals were arbitrarily grouped into low, medium and high
infection levels (100-103, 104-105 and >106 cfu/mg, respectively roughly corresponding to 72, 96 and 120 hours post-infection; UI: uninfected).
(B) Fgf15 transcript levels in the ilea of uninfected mice fed 5% cholestyramine diet. Data by qPCR, **p < 0.01; ***p < 0.001; ****p < 0.0001.
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inflammation-induced cholestasis [28]. This may in turn,
compromise intestinal FXR activation and lead to inhi-
bition of Fgf15, Fabp6, Nr0b2 and Osta expression. To test
whether the depletion of bile acids would be sufficient
to decrease Fgf15 expression in vivo, we fed uninfected
C57BL/6 mice with a diet supplemented with the bile acid
sequestrant cholestyramine. As shown in Figure 3B mice
fed with cholestyramine did have significantly lower levels
of Fgf15 transcripts than mice fed with a normal diet.
Second, we evaluated the effects of Salmonella infection
in bile production and flow. Gallbladder bile volumes were
measured before and during infection; a significant reduc-
tion in volume was observed 24 hours post-infection,
which did not improved over the next 4 days (Figure 4A).
An expression analysis of hepatic genes involved in bileFigure 4 Salmonella infection perturbs the host’s hepatobiliary home
orally infected with Salmonella at the indicated hours post-infection (hpi). (
metabolism in mice infected with Salmonella, relative to the levels of uninf
post-infection. Data by qPCR.synthesis and secretion (Figure 4B), showed striking re-
ductions in the transcript levels of the major transporters
of bile acid and cholesterol (Abcb11, Slc10a1, Abcb1a,
Abcg5 and Abcg8) and the induction of several genes in-
volved in rescue from cholestasis. The mRNA (Figure 5A)
and protein levels (Figure 5B) of CYP7A1, the rate-
limiting enzyme in the neutral pathway of bile acids syn-
thesis, were decreased by infection. This was accompanied
by a significant accumulation of hepatic cholesterol and
triglycerides (Figure 5C and Figure 5D), which collectively
suggest interruption of bile synthesis and flow.
Salmonella infection leads to depletion of the hepatic
FGF15 receptor complex
Signaling of FGF15 in hepatocytes requires the tyrosine
kinase membrane receptor FGFR4 and the proteinostasis. (A) bile volumes recovered from the gallbladders of mice
B) Transcript levels of hepatic genes involved in liver biliary
ected animals (defined as 1, dashed line) at 24, 72 and 120 hours
Figure 5 Salmonella infection downregulates the neutral bile acid synthesis pathway. (A) relative levels of liver Cyp7a1 transcripts in mice
infected with Salmonella. (B) CYP7A1 western blot of liver lysates. (C) Cholesterol and (D) triglycerides accumulation in the liver of Salmonella-infected vs.
uninfected mice, (*p < 0.05; ****p < 0.0001).
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the homeostasis of this pathway, we analyzed the levels
of FGFR4 and βKlotho in infected and uninfected livers.
Figures 6A and 6B show that the transcript levels
of both Fgfr4 and Klb (βKlotho) were significantly de-
creased by infection. In addition, the protein levels were
also reduced, as evidenced by western blot (Figure 6C).
Two major FGFR4 bands were detected in uninfected
animals, with apparent molecular weights of 115 and
125 KDa, likely corresponding to the core-glycosylated
(FGFR4115) and fully-glycosylated, functional (FGFR4125)
forms of FGFR4, respectively [29]. Infection led to the
disappearance of FGFR4125 and a decrease of FGFR4115.
Immunofluorescent staining of liver sections confirmed
the reduction of FGFR4 and βKlotho. Both proteins were
clearly detected in uninfected hepatocytes (Figure 6D);
in contrast, hepatocytes from Salmonella-infected livers
were devoid of FGFR4 and βKlotho.
Discussion
The FGF19-FGFR4 endocrine axis is currently consid-
ered a potential intervention point for the therapy of
cancer, gallstone disease, and metabolic disorders asso-
ciated to the metabolic syndrome [7,30]. Experimental
administrations of FGF19 and transgenic FGF19 mice
have shown decreased liver fat content, improved hepa-
tic and serum lipid profiles, and resistance to high-fatdiet-induced obesity [31-33]. In addition, FGF15/19 in-
duces hepatocyte proliferation [34] and has been recently
identified as an important mediator of liver regeneration
after liver resection surgery [35]. Here we show that
Salmonella infection disturbs the homeostasis of the
FGF15/19-FGFR4 axis by down-regulating the expression
of Fgf15, Fgfr4 and Klb. To our knowledge, these results
constitute the first demonstration of a pathophysiological
effect of bacterial infections over the FGF15/19-FGFR4
endocrine axis.
Infection modified both the ileal expression of Fgf15 and
the components of its hepatic receptor, which suggests a
significant functional shutdown of the pathway. Our data
rules out a direct cytopathic effect of bacteria over ileal
enterocytes as the major cause of Fgf15 mRNA reductions.
Instead, it is apparent that the decline in Fgf15 expression
results from impaired activation of FXR in the enterocytes.
Our interpretation is strongly supported by the observed
low volumes of gallbladder bile and the decreased expres-
sion of Fabp6, Ostα and Nr0b2 (Shp), all well-known FXR
targets. In addition, we show that the depletion of the
intestinal bile acids pool by oral administration of the bile
acid sequestrant cholestyramine is sufficient to signifi-
cantly decrease ileal Fgf15 expression. Furthermore, intra-
venous infections with a Salmonella invasion mutant and
with Listeria monocytogenes, both resulting in rapid hepa-
tic colonization and pathophysiology, lead to reductions in
Figure 6 Salmonella infection causes the loss of the hepatic FGF15 receptor complex. (A) relative levels of Fgfr4 and (B) Klb (βKlotho)
transcripts in the livers of mice infected with Salmonella. The animals analyzed in (A) and (B) are from the high-infection group in Figure 1, the
data is by qPCR, (**p < 0.01; ***p < 0.001). (C) FGFR4 and βKlotho western blots of liver lysates. (D) FGFR4 and βKlotho immunostaining of
uninfected (top panel) and Salmonella-infected (bottom panel) liver samples. The figure shows a single, representative hepatocyte in each case.
Scale bar is 5 μm.
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terial colonization or enterocyte invasion.
Salmonella infection induced a massive alteration of the
hepatobiliary gene expression program. Remarkably, the
mRNA and protein levels of CYP7A1, the rate-limiting
enzyme in the neutral pathway of bile acids synthesis were
decreased during infection, in spite of the lower levels of
FGF15 which would be expected to promote the upregu-
lation of Cyp7a1 expression. These results reveal the
complexities in the regulation of Cyp7a1 expression and
indicates that the mechanisms of Cyp7a1 expression con-
trol are hierarchical. Infection also triggered a significant
reduction of FGFR4 and βKlotho, the two proteins in-
volved in assembling the functional receptor for FGF15 in
hepatocytes. The biology of FGFR4 and βKlotho had never
before been studied in the context of a bacterial insult,
and our data suggest that their function can be severely
compromised by bacterial infections in vivo. The mecha-
nisms underlying their downregulation are unclear at
present but we anticipate that they are related to the pro-
inflammatory cytokine burst that follows liver colonization
by bacteria. It has been recently reported that TNFαrepresses βKlotho expression in adipocytes [36]; thus it is
possible that a similar mechanism acts in hepatocytes.
It is apparent that the dysregulation of the FGF15/19-
FGFR4 endocrine axis components is not a general
pathogenic feature of all bacteria, as infections with
the enteric pathogen Citrobacter rodentium, the mouse
model for human EPEC and EHEC [37], did not modify
the expression of ileal Fgf15 (data not shown). Instead,
this pathophysiological effect may be restricted to infec-
tions displaying a relevant liver involvement. Further
work is still necessary to define the full impact of infec-
tions in FGF15/19 function and to determine the under-
lying molecular mechanisms.
Conclusions
Through the alteration of the hepatobiliary function,
bacterial pathogens of the enterohepatic system dysregu-
late the homeostasis of the FGF15/19-FGFR4 endocrine
axis. These revealing findings have important implica-
tions for the understanding of the pathophysiology of
microbial diseases. Disruption of the FGF15/19-FGFR4
pathway may be a contributing factor to the metabolic
Romain et al. BMC Microbiology 2013, 13:238 Page 9 of 10
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diseases.
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